A Phase 2 interventional study of AG-013736 in Thyroid Neoplasms, sponsored by Pfizer. Completed at 26 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.
Sponsored by Pfizer · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Thyroid Neoplasms with a site in United States — 54 open to participants now, 90 under way, 3 of them phase 3. Thyroid Neoplasms · United States.
Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 85th largest by enrollment of the 231 interventional ones that give a count, is one of 12 that started in 2006, is one of 99 in phase 2, and was the 41st registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
Browse Thyroid Neoplasms studies →54 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Thomas Hope · Sites in United States
Ages 12+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 120 · Phase 3 10 · Phase 4 5
First in 1977; this study’s year is marked. 12 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 231 interventional studies, 200 across the 47 observational. Of the 180 that completed or were terminated, 93 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 283 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
27 of the studies in Thyroid Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023731Arvinas Inc.A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | 2026-11-30 |
| NCT03099356University of Michigan Rogel Cancer CenterCyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | 2026-12 |
| NCT06220656Dartmouth-Hitchcock Medical CenterTRAIL Study: Feasibility and Pilot | 2026-12 |
| NCT05366881Adela, InccfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | 2026-12-31 |
| NCT06207188Mayo ClinicIdentification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | 2026-12-31 |
Add all 27 to your calendar (.ics) → With an account.
Among the 283 studies in Thyroid Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
Additional study details: assess safety and efficacy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG-013736
AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). CR: disappearance of all target/non-target lesions and no appearance of new lesions. PR: at least (\>=)30 percent(%) decrease in sum of the longest dimensions (LDs) of the target lesions (taking as a reference the baseline sum), without progression of non-target lesions and no appearance of new lesions. Confirmed responses: those persist on repeat imaging study \>=4 weeks after initial documentation of response.
Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Progression Free Survival (PFS)
PFS: Time in weeks from the start of study treatment to first documentation of objective disease progression or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of first dose of study treatment plus 1) divided by 7. Progression is defined using RECIST, as \>=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD since start of study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Duration of Response (DR)
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until disease progression or initiation of antitumor therapy or death due to any cause, assessed every 8 weeks up to 28 days after last dose (follow-up)
Overall Survival (OS)
Time in weeks from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline to death due to any cause or at least 2 year after the first dose for the last participant
Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Severity Score
Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling). Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Total average score range: 0 to 10. Lower scores indicated better outcome.
Time frame: Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)
Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Interference Score
Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life). Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Total average score range: 0 to 10. Lower scores indicated better outcome.
Time frame: Baseline, Cycle 1 Day 15 (C1D15), C2D1, C2D15, thereafter D1 of each cycle up to 28 days after last dose (follow-up)
| Milestone | Axitinib |
|---|---|
| Started | 52 |
| Completed | 0 |
| Not completed | 52 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Physician decision | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Global deterioration of health status | 4 |
| Withdrew: Objective progression or relapse | 26 |
| Withdrew: Ongoing in study a4061008 (nct00828919) | 2 |
| Withdrew: Clinical progression | 1 |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). CR: disappearance of all target/non-target lesions and no appearance of new lesions. PR: at least (\>=)30 percent(%) decrease in sum of the longest dimensions (LDs) of the target lesions (taking as a reference the baseline sum), without progression of non-target lesions and no appearance of new lesions. Confirmed responses: those persist on repeat imaging study \>=4 weeks after initial documentation of response.
| percentage of participants | Axitinib |
|---|---|
| Percentage of Participants With Objective Response (OR) | 34.6 (22.0 to 49.1) |
PFS: Time in weeks from the start of study treatment to first documentation of objective disease progression or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of first dose of study treatment plus 1) divided by 7. Progression is defined using RECIST, as \>=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD since start of study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| weeks | Axitinib |
|---|---|
| Progression Free Survival (PFS) | 70.14 (64.14 to 93.71) |
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| weeks | Axitinib |
|---|---|
| Duration of Response (DR) | 74.71 (59.14 to 112.29) |
Time in weeks from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| weeks | Axitinib |
|---|---|
| Overall Survival (OS) | 118.43 (63.57 to 174.57) |
Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling). Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Total average score range: 0 to 10. Lower scores indicated better outcome.
| units on a scale | Axitinib |
|---|---|
| Baseline (n= 49) | 1.66 ± 1.301 |
| Change at C1D15 (n= 40) | 0.18 ± 1.158 |
| Change at C2D1 (n= 42) | 0.43 ± 1.274 |
| Change at C2D15 (n= 37) | 0.52 ± 1.407 |
| Change at C3D1 (n= 43) | 0.53 ± 1.602 |
| Change at C4D1 (n= 39) | 0.58 ± 1.199 |
| Change at C5D1 (n= 36) | 0.69 ± 1.550 |
| Change at C6D1 (n= 36) | 0.53 ± 1.484 |
| Change at C7D1 (n= 29) | 0.40 ± 1.344 |
| Change at C8D1 (n= 28) | 0.44 ± 1.395 |
| Change at C9D1 (n= 27) | 0.56 ± 1.516 |
| Change at C10D1 (n= 25) | 0.59 ± 1.494 |
| Change at C11D1 (n= 25) | 0.63 ± 1.669 |
| Change at C12D1 (n= 24) | 0.59 ± 1.584 |
| Change at C13D1 (n= 24) | 0.60 ± 1.281 |
| Change at C14D1 (n= 24) | 0.59 ± 1.476 |
| Change at C15D1 (n= 24) | 0.76 ± 1.654 |
| Change at C16D1 (n= 23) | 0.81 ± 1.911 |
| Change at C17D1 (n= 20) | 0.73 ± 1.816 |
| Change at C18D1 (n= 20) | 0.60 ± 1.729 |
| Change at C19D1 (n= 18) | 0.40 ± 1.201 |
| Change at C20D1 (n= 16) | 0.50 ± 0.864 |
| Change at C21D1 (n= 16) | 0.84 ± 1.094 |
| Change at C22D1 (n= 15) | 0.61 ± 0.970 |
| Change at C23D1 (n= 14) | 0.87 ± 1.086 |
| Change at C24D1 (n= 11) | 1.05 ± 0.990 |
| Change at C25D1 (n= 11) | 0.87 ± 1.016 |
| Change at C26D1 (n= 9) | 1.15 ± 0.960 |
| Change at C27D1 (n= 9) | 1.19 ± 1.244 |
| Change at C28D1 (n= 10) | 0.95 ± 1.291 |
| Change at C29D1 (n= 10) | 0.98 ± 1.080 |
| Change at C30D1 (n= 10) | 1.03 ± 0.970 |
| Change at C31D1 (n= 9) | 1.14 ± 1.100 |
| Change at C32D1 (n= 9) | 1.44 ± 1.058 |
| Change at C33D1 (n= 9) | 1.32 ± 1.233 |
| Change at C34D1 (n= 8) | 1.54 ± 1.366 |
| Change at C35D1 (n= 6) | 1.29 ± 1.233 |
| Change at C36D1 (n= 6) | 1.27 ± 1.610 |
| Change at C37D1 (n= 5) | 1.48 ± 1.347 |
| Change at C38D1 (n= 5) | 1.27 ± 1.117 |
| Change at C39D1 (n= 5) | 1.49 ± 1.288 |
| Change at C40D1 (n= 5) | 1.47 ± 1.176 |
| Change at C41D1 (n= 5) | 1.48 ± 1.267 |
| Change at C42D1 (n= 5) | 1.59 ± 1.312 |
| Change at C43D1 (n= 5) | 1.59 ± 1.259 |
| Change at C44D1 (n= 5) | 1.42 ± 1.258 |
| Change at C45D1 (n= 4) | 1.49 ± 1.349 |
| Change at C46D1 (n= 4) | 1.73 ± 1.425 |
| Change at C47D1 (n= 4) | 1.70 ± 1.543 |
| Change at C48D1 (n= 3) | 1.90 ± 1.377 |
| Change at C49D1 (n= 3) | 2.26 ± 1.554 |
| Change at C50D1 (n= 3) | 2.38 ± 1.425 |
| Change at C51D1 (n= 3) | 2.46 ± 1.533 |
| Change at C52D1 (n= 1) | 3.38 ± NA |
| Change at C53D1 (n= 1) | 3.54 ± NA |
| Change at C54D1 (n= 1) | 3.00 ± NA |
| Change at C55D1 (n= 1) | 3.38 ± NA |
| Change at C56D1 (n= 1) | 3.15 ± NA |
| Change at C57D1 (n= 1) | 3.62 ± NA |
| Change at C58D1 (n= 1) | 3.23 ± NA |
| Change at C59D1 (n= 1) | 3.08 ± NA |
| Change at C60D1 (n= 1) | 3.85 ± NA |
| Change at C61D1 (n= 1) | 3.31 ± NA |
| Change at C62D1 (n= 1) | 3.46 ± NA |
| Change at follow-up (n= 12) | 0.37 ± 0.939 |
Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life). Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Total average score range: 0 to 10. Lower scores indicated better outcome.
| units on a scale | Axitinib |
|---|---|
| Baseline (n= 48) | 2.24 ± 2.193 |
| Change at C1D15 (n= 40) | -0.05 ± 2.161 |
| Change at C2D1 (n= 41) | 0.28 ± 2.763 |
| Change at C2D15 (n= 36) | 0.67 ± 2.403 |
| Change at C3D1 (n= 42) | 0.46 ± 2.669 |
| Change at C4D1 (n= 37) | 0.47 ± 2.311 |
| Change at C5D1 (n= 36) | 0.50 ± 2.377 |
| Change at C6D1 (n= 36) | 0.65 ± 2.605 |
| Change at C7D1 (n= 29) | 0.19 ± 2.386 |
| Change at C8D1 (n= 28) | 0.22 ± 2.242 |
| Change at C9D1 (n= 27) | 0.46 ± 2.450 |
| Change at C10D1 (n= 25) | 0.35 ± 2.386 |
| Change at C11D1 (n= 25) | 0.51 ± 2.784 |
| Change at C12D1 (n= 23) | 0.32 ± 2.593 |
| Change at C13D1 (n= 24) | 0.42 ± 2.346 |
| Change at C14D1 (n= 24) | 0.42 ± 2.624 |
| Change at C15D1 (n= 24) | 0.69 ± 2.902 |
| Change at C16D1 (n= 23) | 0.73 ± 3.179 |
| Change at C17D1 (n= 20) | 0.26 ± 2.920 |
| Change at C18D1 (n= 20) | 0.35 ± 2.638 |
| Change at C19D1 (n= 18) | -0.18 ± 2.497 |
| Change at C20D1 (n= 15) | 0.30 ± 2.124 |
| Change at C21D1 (n= 15) | 0.50 ± 1.954 |
| Change at C22D1 (n= 14) | 0.32 ± 1.979 |
| Change at C23D1 (n= 14) | 0.95 ± 1.615 |
| Change at C24D1 (n= 11) | 0.77 ± 1.844 |
| Change at C25D1 (n= 11) | 0.65 ± 1.699 |
| Change at C26D1 (n= 9) | 1.04 ± 1.681 |
| Change at C27D1 (n= 9) | 0.81 ± 2.463 |
| Change at C28D1 (n= 28) | 0.67 ± 1.956 |
| Change at C29D1 (n= 29) | 0.88 ± 1.926 |
| Change at C30D1 (n= 30) | 1.03 ± 1.846 |
| Change at C31D1 (n= 9) | 1.19 ± 1.910 |
| Change at C32D1 (n= 9) | 1.52 ± 1.870 |
| Change at C33D1 (n= 9) | 1.07 ± 1.972 |
| Change at C34D1 (n= 8) | 1.81 ± 1.846 |
| Change at C35D1 (n= 6) | 1.17 ± 1.517 |
| Change at C36D1 (n= 6) | 0.97 ± 1.572 |
| Change at C37D1 (n= 5) | 1.40 ± 1.782 |
| Change at C38D1 (n= 5) | 1.23 ± 1.521 |
| Change at C39D1 (n= 5) | 1.50 ± 1.453 |
| Change at C40D1 (n= 5) | 1.83 ± 1.889 |
| Change at C41D1 (n= 5) | 1.53 ± 1.746 |
| Change at C42D1 (n= 5) | 1.67 ± 1.637 |
| Change at C43D1 (n= 5) | 1.31 ± 1.267 |
| Change at C44D1 (n= 5) | 1.34 ± 1.345 |
| Change at C45D1 (n= 4) | 1.50 ± 1.694 |
| Change at C46D1 (n= 4) | 2.17 ± 2.113 |
| Change at C47D1 (n= 4) | 1.63 ± 1.950 |
| Change at C48D1 (n= 3) | 2.00 ± 1.041 |
| Change at C49D1 (n= 3) | 2.56 ± 1.798 |
| Change at C50D1 (n= 3) | 0.22 ± 1.206 |
| Change at C51D1 (n= 3) | 2.44 ± 1.251 |
| Change at C52D1 (n= 1) | 3.33 ± NA |
| Change at C53D1 (n= 1) | 3.33 ± NA |
| Change at C54D1 (n= 1) | 3.33 ± NA |
| Change at C55D1 (n= 1) | 3.50 ± NA |
| Change at C56D1 (n= 1) | 3.50 ± NA |
| Change at C57D1 (n= 1) | 4.50 ± NA |
| Change at C58D1 (n= 1) | 3.67 ± NA |
| Change at C59D1 (n= 1) | 3.33 ± NA |
| Change at C60D1 (n= 1) | 4.83 ± NA |
| Change at C61D1 (n= 1) | 3.33 ± NA |
| Change at C62D1 (n= 1) | 4.00 ± NA |
| Change at follow-up (n= 12) | 0.32 ± 2.396 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | — | 22/52 (42.3%) | 52/52 (100%) |
| Event | Axitinib |
|---|---|
| FatigueGeneral disorders | 3/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/52 |
| Disease progressionGeneral disorders | 2/52 |
| Weight decreasedInvestigations | 2/52 |
| Cardiac failure congestiveCardiac disorders | 1/52 |
| Hypertensive heart diseaseCardiac disorders | 1/52 |
| Myocardial infarctionCardiac disorders | 1/52 |
| Myocardial ischaemiaCardiac disorders | 1/52 |
| HaematemesisGastrointestinal disorders | 1/52 |
| Oral painGastrointestinal disorders | 1/52 |
| Event | Axitinib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 31/52 |
| HypertensionVascular disorders | 28/52 |
| FatigueGeneral disorders | 23/52 |
| Decreased appetiteMetabolism and nutrition disorders | 19/52 |
| Weight decreasedInvestigations | 18/52 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 16/52 |
| NauseaGastrointestinal disorders | 14/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/52 |
| Mucosal inflammationGeneral disorders | 10/52 |
| Age Continuous(years) | Axitinib |
|---|---|
| Mean | 57.6 ± 12.1 |
| Sex: Female, Male(Participants) | Axitinib |
|---|---|
| Female | 24 |
| Male | 28 |
The record gives a start of Dec 2006, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib